BIODEXA PHARMACEUTICALS PLC (BDRX) earnings per share

BIODEXA PHARMACEUTICALS PLC reports in GBP; the per-share figures below are in GBP as filed with SEC EDGAR, not US dollars.
Annual history
Fiscal years 2022 – 2025
GBP / SHARE 4 PERIODS
Period End Diluted Filed
FY 2025 2025-12-31 -£0.00 2026-03-27
FY 2024 2024-12-31 -£0.00 2025-04-11
FY 2023 2023-12-31 -£0.02 2024-04-19
FY 2022 2022-12-31 -£1.55 2023-04-28
Quarterly history
Fiscal years 2022 – 2024
GBP / SHARE 3 PERIODS
Period End Diluted Filed
Q2 2024 2024-06-30 £0.10 2024-09-26
Q2 2023 2023-06-30 £3.60 2023-09-29
Q2 2022 2022-06-30 -£62.00 2022-10-04
Free cash flow per share — Annual
Fiscal years 2022 – 2025 · (Operating CF − CapEx) ÷ Diluted Shares
GBP / SHARE 4 PERIODS
Period End FCF / Share Filed
FY 2025 2025-12-31 -£0.00 2026-03-27
FY 2024 2024-12-31 -£0.00 2025-04-11
FY 2023 2023-12-31 -£0.02 2024-04-19
FY 2022 2022-12-31 -£1.44 2023-04-28
Free cash flow per share — Quarterly
Fiscal years 2023 · (Operating CF − CapEx) ÷ Diluted Shares
GBP / SHARE 1 PERIODS
Period End FCF / Share Filed
Q2 2023 2023-06-30 -£3.92 2023-09-29

Methodology

Annual rows come from the filer's 10-K and Q1–Q3 rows from the matching 10-Q; Q4 is derived as full-year minus nine-month YTD because XBRL doesn't tag Q4 as its own period. EPS Basic and EPS Diluted are reported directly by the filer. FCF / Share is computed as (Operating Cash Flow − Capital Expenditures) ÷ Diluted Shares Outstanding. When SEC companyfacts omits the direct diluted-share concept for an older period, we imply it from NetIncomeLoss ÷ EarningsPerShareDiluted. For financial filers whose operating cash flow includes customer-fund activity (e.g. Mercado Pago deposits), FCF may materially exceed net income because the fintech float is recorded inside OCF under US GAAP. Per-share values are split-adjusted to the current share count (8 split s since 2019).

For the exact XBRL concepts and formulas, see the methodology reference for EPS, FCF per share, the Q4 derivation, and split adjustment.

FCF source tags per fiscal year (4 periods)

The exact namespace:concept that fed Operating Cash Flow, CapEx, and the diluted-share denominator for each annual FCF / Share value. Filers swap between fallback concepts over the years (e.g. PaymentsToAcquireProductiveAssetsPaymentsToAcquirePropertyPlantAndEquipment), and older periods where SEC companyfacts omits the direct shares tag fall back to an implied share count from Net Income ÷ EPS Diluted.

Period Operating CF CapEx Diluted Shares
FY 2022 ifrs-full:CashFlowsFromUsedInOperatingActivities ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities implied ifrs-full:ProfitLoss ÷ ifrs-full:DilutedEarningsLossPerShare
FY 2023 ifrs-full:CashFlowsFromUsedInOperatingActivities ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities implied ifrs-full:ProfitLoss ÷ ifrs-full:DilutedEarningsLossPerShare
FY 2024 ifrs-full:CashFlowsFromUsedInOperatingActivities ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities implied ifrs-full:ProfitLoss ÷ ifrs-full:DilutedEarningsLossPerShare
FY 2025 ifrs-full:CashFlowsFromUsedInOperatingActivities ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities implied ifrs-full:ProfitLoss ÷ ifrs-full:DilutedEarningsLossPerShare

BDRX CIK 0001643918 Source: EDGAR filings · all facts

Related tickers

GASS

STEALTHGAS INC.

PHR

PHREESIA, INC.

AHR

American Healthcare REIT, Inc.